**Supplementary Figure 1.** Risk score-related genes and clinical characteristics in GSE31312 (A) and GSE117556 (B) patients. ECOG: Eastern Cooperative Oncology Group score, IPI: International Prognostic Index, ABC: activated B-cell-like, GCB: germinal center B-cell-like, R-CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab, BR-CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab and bortezomib.
**Supplementary Figure 2.** Distribution of immune checkpoint gene expression in GSE31312 patients.

**Supplementary Figure 3.** Distribution of immune checkpoint gene expression in GSE117556 patients.
Supplementary Figure 4. Risk score-related immune expression patterns in GSE10846 (A) and GSE31312 (B) patients.
Supplementary Figure 5. Risk score-related T cell-specific immunity in GSE10846 (A) and GSE31312 (B) patients.